Urothelial Carcinoma Prognosis. In general, urothelial carcinoma is a highly treatable cancer. If found early, the cancer can be removed by surgery and usually will not come back.

Papillary urothelial carcinoma is a type of bladder cancer. It is often slow growing, and effective treatment is possible in many cases. Find out more.

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.. The ...

Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. In this open-label, international, phase 3 trial ...

Urothelial carcinoma (UC), which can involve the urethra, bladder, and upper tracts is the sixth most commonly diagnosed cancer in Western countries. 1 Radical cystectomy (RC) with pelvic lymph ...

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s ...

Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. ... The median disease-free survival was 29.6 months (95% confidence interval [CI], ...

The urinary comprehensive genomic profiling (uCGP) assay (UroAmp, Convergent Genomics) had a specificity of 90% and sensitivity of 95% for an initial diagnosis of urothelial carcinoma in patients ...

Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000;56:228–231.